Take­da dou­bles down at Cal­i­for­nia site as it looks to grow rare dis­ease man­u­fac­tur­ing base

Japan­ese drug­mak­er Take­da is look­ing to ramp up the ef­fi­cien­cy of its rare dis­eases man­u­fac­tur­ing, which in­cludes pro­grams for he­mo­phil­ia and Von Wille­brand dis­ease. It will turn to a Cal­i­for­nia lo­ca­tion it’s fa­mil­iar with to bring its op­er­a­tions in­to the fu­ture.

Take­da will more than dou­ble the size of its Thou­sand Oaks, CA man­u­fac­tur­ing site in an up­grade that will use au­toma­tion, ro­bot­ics and dig­i­ti­za­tion to re­duce the po­ten­tial for hu­man er­ror, the com­pa­ny said in a re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.